Ruxolitinib: a targeted treatment option for patients with polycythemia vera
Kris Vaddi,1 Srdan Verstovsek,2 Jean-Jacques Kiladjian3 1Drug Discovery, Incyte Corporation, Wilmington, DE, 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Clinical Investigations Center, Hôpital ...
Kiladjian JJ, Vaddi K, Verstovsek S
core
Hematological trajectories and pregnancy complications in essential thrombocythemia and polycythemia vera. [PDF]
Klok FR +9 more
europepmc +1 more source
Modern and multidisciplinary care in polycythemia vera. [PDF]
Palandri F +20 more
europepmc +1 more source
Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis. [PDF]
Bakht D +12 more
europepmc +1 more source
Masked Triple-Negative Polycythemia Vera Initially Presenting as Iron Deficiency and Pernicious Anemia. [PDF]
Nedjar OG +8 more
europepmc +1 more source
Hyperviscosity encephalopathy in suspected polycythemia vera at high altitude: a case report. [PDF]
Yao S, Chen X.
europepmc +1 more source
Recent trends in hospitalizations for myelodysplastic syndromes and polycythemia vera in England and Wales. [PDF]
Alsharif AA, Naser AY, Ofori-Asenso R.
europepmc +1 more source
Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia. [PDF]
Loscocco GG +11 more
europepmc +1 more source
A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. [PDF]
Palandri F +26 more
europepmc +1 more source

